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Abstract
Background: Many emerging new drugs have recently been trialled for treatment of early and
advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role,
mostly in patients with relapsed and metastatic disease after failure of chemotherapy with
antracyclines.
Methods:  A phase II study was started in order to evaluate the activity and toxicity of a
combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer
patients previously treated with antracyclines.
Results: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by
gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1–14) for a maximum of eight cycles.
In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a
complete response, 12 (48%) a partial response giving an overall objective response rate of 64%.
Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients
(16%).
Conclusion: The schedule of treatment was safe and tolerable from a haematological and non-
haematological point of view. These data confirm that the combination of gemcitabine and
paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients
with prior therapeutic exposure to antracyclines.
Background
Despite the availability of new, active drugs, metastatic
breast cancer (MBC) remains an incurable disease, and
the treatment of it is still controversial. In fact, the best
treatment for patients pretreated with antracyclines, a sub-
set very common in clinical practice, is hotly debated,
given the extensive use of doxorubicine and epirubicine in
metastatic, adjuvant and neoadjuvant settings.
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Nevertheless, today the treatment of MBC is a rational
choice, as different studies have shown that the use of
polichemotherapy in this subset of patients appears to
improve long term remission, relapse-free survival and
overall survival [1-4].
In recent years, novel drugs have emerged as important
agents in the treatment of MBC patients, because of their
safety and efficacy in generating symptom relief, in reduc-
ing disease progression and in prolonging survival.
Among these new agents, taxanes have become the stand-
ard therapy in patients pretreated with antracyclines. In
this subset of patients paclitaxel as a single agent has gen-
erated response rates ranging from 6% to 48% [5,6] and
these results improved when the drug was used as first line
treatment in metastatic disease[7]. Actually a number of
newer cytotoxic agents have been introduced in clinical
trials to evaluate novel, safe and active taxane-based com-
binations in the treatment of MBC, extensively pretreated
with antracyclines.
Gemcitabine is a cytidine nucleoside analogue with
proven activity in advanced breast cancer.
In previously treated MBC patients it has produced
response rates ranging from 12% to 29%, and it was toler-
ated satisfactorily [8,9], while in first line schedules the
response rate reported was 14–37% [10].
The paclitaxel and gemcitabine combination is justified
by their different mechanism of action and by the lack of
overlapping toxicities. In MBC this combination has been
evaluated in phase II studies using a three -weekly sched-
ule of treatment with paclitaxel given at 175 mg/mq on
day 1 and gemcitabine given at 1000–1250 mg/mq on
days 1,8, showing an interesting response rate ranging
from 45% to 55% [11,12]. Recently an interim analysis of
a large phase III study demonstrated that the combination
of paclitaxel plus gemcitabine as first-line treatment was
more efficacious than paclitaxel alone in MBC, according
to the different clinical variables considered (progression-
free survival, response rate, pain relief and QOL)[13].
In a phase II study the combination of paclitaxel and gem-
citabine was explored in a biweekly schedule by Colomer
et al. in 1998 in a subset of patients who had not received
prior treatment for MBC [14]. In this trial the response
rate was impressive with an overall response of 69% (24%
CR), and was well tolerated.
The same authors have recently updated these data in
untreated MBC patients, with an overall response rate of
71% (26% CR). Moreover, in the same study it was dem-
onstrated that the efficacy of this schedule could be
reduced by elevated levels of HER2 [15].
According to these results a phase II study was started to
evaluate the efficacy and tolerability of a biweekly sched-
ule of paclitaxel and gemcitabine in MBC patients pre-
treated with antracyclines.
Methods
Eligibility
To be elegible for the study, patients were required to have
histologically confirmed breast cancer, metastatic or
locally advanced disease, bidimensionally measurable
lesions, performance status ≥ 70%, age 18–75 ys, ade-
quate bone marrow, hepatic and renal function (neu-
trophil count ≥ 1500/µL, platelets ≥ 100,000 µL,
hemoglobin ≥ 10 g/L, bilirubin ≤ 2 mg/dl, creatinine 1.5
≤ mg/dl, and alanine/aspartate amino transferase level ≤ 3
times above normal). Prior chemotherapy, excluding
gemcitabine and taxanes, radiotherapy and endocrine-
therapy were permitted. All the patients were required to
have received prior chemotherapy with antracyclines, in
neoadjuvant, adjuvant and metastatic setting. Patients
were excluded from the study in cases of: brain metastases,
peripheral neuropathy and vasculopathy, bone metas-
tases as the only site of disease, history of active cardiac
disease, previous malignant neoplasia, pregnancy and
breast feeding, any antineoplastic treatment within 8
weeks of entering the study
.
Treatment plan
Study treatment consisted of the infusion of gemcitabine
and paclitaxel according to a biweekly schedule. Patients
received paclitaxel (150 mg/mq) in 3-hours infusion, fol-
lowed by gemcitabine (2000 mg/mq) given as a 60 min
i.v. infusion. Patients received standard premedication
with i.v. dexamethasone (20 mg) and antiemetic treat-
ment 1 hour before the start of therapy with paclitaxel,
plus orphenadrine and cimetidine.
Patients were scheduled to receive a maximum of 8 cycles
and chemotherapy was stopped in case of progression,
patient refusal and unacceptable toxicity. Patients who
had received at least one course of chemotherapy were
evaluated for toxicity and at least two courses for efficacy.
The toxicity and activity of the schedule were evaluated
according to the WHO criteria. [16]. All the measurable
lesions were evaluated at baseline and after every two
courses in order to document any response, stable disease
or progressive disease.
Complete response was defined as the disappearance of
all measurable lesions, partial response as the decrease ofBMC Cancer 2006, 6:137 http://www.biomedcentral.com/1471-2407/6/137
Page 3 of 5
(page number not for citation purposes)
more than 50% of the sum of the products of all the meas-
ured lesions with no occurrence of new lesions, stable dis-
ease as a reduction ranging from 25% to 50% of the sum
of the products of all the measured lesions with no occur-
rence of new lesions and progressive disease as an increase
> 25% of the sum of the products of all the measured
lesions or the occurrence of new lesions.
All the patients were required to give written informed
consent before the start of treatment and the study was
conducted according to the approval of the local ethical
board (Azienda Policlinico Umberto I – Ethical Commit-
tee)
Results
Patients characteristics
Twenty-five consecutive patients with metastatic breast
cancer and measurable disease were recruited by the
Department of Experimental Medicine La Sapienza Uni-
versity of Rome in order to assess the tolerability and effi-
cacy of a biweekly schedule of paclitaxel and gemcitabine.
All the patients had received prior chemotherapy with
antracyclines in adjuvant and non adjuvant settings and
sixteen of them have been treated for metastatic disease.
All the patients were evaluated for toxicity and efficacy.
The main characteristic of the patients are shown in table
1.
The median age was 51 years and the youngest patient
enrolled was 39 years old. The majority of patients pre-
sented a WHO performance status of 0 (80%). All the
patients had received prior treatment with antracyclines
(44 % in adjuvant setting). At diagnosis lung and liver
involvement was detected in 15 patients (60% with dom-
inant visceral disease).
Efficacy
A total of 148 cycles were given in an output basis with a
median of seven per patient.
Four patients (16%) achieved a complete response, 12
(48%) a partial response, with an overall objective
response rate of 64%. Stable disease was documented in 5
patients (20%) while progressive disease occurred in 4
patients(16%).
After an average follow-up of 18 months, the median
duration of response in the subset of responders was 11.5
months with twelve patients alive.
Table 2 shows the response rates observed in the study.
Toxicity
Toxicity data were available for all the patients recruited.
Treatment was well tolerated in almost all the patients
with infrequent occurrence of 3–4 grade toxicity.
The most frequent toxicity was haematological : two
patients experienced grade 4 neutropenia and one grade 4
thrombocytopenia; grade 3 neutropenia occurred in 24%
of patients; thrombocytopenia in 16% and anemia in
12%. No febrile neutropenia was observed and none of
the patients received platelet transfusion. No toxic death
or hospitalisation occurred.
Grade 2 peripheral neuropathy was frequent, mainly as
grade 1–2 (38% of cases).
Table 2: Response rates
Response No of patients (%)
Complete response 4 (16)
Partial response 12(48)
Overall response 16(64)
Stable disease 5 (20)
Progressive disease 4(16)
Table 1: Characteristics of patients (n.25)
Characteristic n(%)
Age (years)
Median 51
Range 39–69
P. S 0–1 20(80%)
P. S 2 5 (20%)
Histology
Infiltrating ductal ca 19 (76)
Infiltrating lobular ca 6 (14)
Estrogen status
ER+ 14 (56)
ER - 7 (28)
Unknown 4 (16)
Dominant sites of metastases
Nodes 10(40)
Soft tissues 2(8)
Bone 5(20)
Liver 8(32)
Lung 7(28)
Pretreatment with antracyclines
Adjuvant CT 11(44)
Not adjuvant CT 14(56)BMC Cancer 2006, 6:137 http://www.biomedcentral.com/1471-2407/6/137
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Complete alopecia occurred in almost all the patients
treated.
Dose reduction or delays were necessary in less than 10%
of chemotherapy cycles.
A summary of the toxicity data is reported in Table 3.
Discussion
Although advanced and relapsing breast cancer is gener-
ally considered an incurable disease, many opportunities
have been explored in recent years to achieve an efficient
palliation with the combined use of chemotherapy, radi-
otherapy, endocrine therapy and supportive treatment
Systemic chemotherapy must be considered the treatment
of choice in this subset of patients, in particular when
endocrine resistance occurs. Antracyclines still constitute
the cornerstone of chemotherapeutic approaches in
advanced breast cancer, while the problem of the best
schedule of treatment when an antracycline resistance
occurs still has to be resolved.
In monochemotherapy, paclitaxel has shown interesting
activity in doxorubicin-refractory metastatic breast cancer
(28–48% response rate) and many phase II and III trials
have investigated its optimal combination with other
anticancer drugs. Among the new agents investigated in
the treatment of advanced breast cancer, gemcitabine has
demonstrated unexpected activity with response rates
ranging from 15% to 40% when used as single agent in
first- and second-line therapy. Moreover, the choice of this
drug in the treatment od relapsing and metastatic breast
cancer is conditioned by its toxicity profile. According to
these data, the combination of paclitaxel and gemcitabine
in patients with advanced and metastatic breast cancer
and pretreated with antracyclines has recently been inves-
tigated in some trials. Nevertheless, the best schedule of
treatment with a combination of the two drugs is still
under investigation (weekly, biweekly, etc...), and other
studies are necessary to address this question, in particular
when gemcitabine and paclitaxel are used in triplet sched-
ules, in combination with other traditional or innovative
drugs.
For this reason we investigated the toxicity and the clinical
activity of the combination of gemcitabine and paclitaxel
according to the schedule reported by Colomer [14] with
a biweekly infusion of the two drugs in untreated patients
with metastatic breast cancer.
In our study the dose of gemcitabine was lower than that
reported by Colomer (2000 mg/mq vs 2500 mg/mq),
using gemcitabine with precaution in our group of heavily
pretreated patients.
In spite of this reduction the response rate in our experi-
ence was surprisingly high, although the patients had
received two and more lines of treatment in the past.
Moreover, only sixteen patients experienced progressive
disease during the treatment, confirming the activity of
the combination of gemcitabine and paclitaxel in the pal-
liative therapy of metastatic breast cancer.
The favourable toxicity profile of this schedule was con-
firmed by the satisfactory results of other studies, and led
to testing of this schedule in combination with new drugs
with different biological activity (trastuzumab, tyrosine
kinase and VEGF inhibitors). Moreover, these data suggest
that the introduction of the combination as first line treat-
ment of MBC should be explored more extensively only
after its activity as second line treatment in better under-
stood and the best schedule of infusion has been identi-
fied.
Thus, some questions arise from this and other studies.
With this novel combination which schedule of treatment
in the best, weekly or biweekly? With the gemcitabine/
paclitaxel combination which is the right dose and is
intensification or acceleration of the dose possibility? Is
this combination a valid alternative in first-line treatment
of patients not candidate to receive chemotherapy with
antracyclines for clinical and biological reasons?
Conclusion
The study reported in this paper presents an evident meth-
odological limit: the number of patients enrolled; in spite
of the strong evidence in literature activity of the combi-
nation of gemcitabine and paclitaxel in metastatic breast
cancer, the papers recently published in this field present
the same limit.
This evidence data support further testing of this combi-
nation in a larger randomized phase III clinical trial.
Unfortunately because there is not a standard in the
choice of the best chemotherapeutic treatment of meta-
static breast cancer resistant to anthracyclines, it is difficult
to design a randomized trial to compare this novel associ-
ation (on weekly or biweekly schedule) with a control
Table 3: Hematological and non-hematological toxicity(% 
patients)
Toxicity Grade 3 Grade 4
Anaemia 12 -
Neutropenia 24 8
Trombocytopenia 16 4
Neuropathy - -
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scheme of treatment. Moreover this clinical limitation is
complicated by the extensive use of taxanes in first line
chemotherapy of breast cancer and therefore the gold
standard after anthracyclines/taxanes failure is fat to be
identified.
Nevertheless it is evident that there is a strong indication
to start also with a III phase trial to compare the weekly
with the biweekly schedule ; moreover it will be very inter-
esting to evaluate the role of emerging prognostic factors
(e.g. HER2/neu gene amplification, VEGF, e-cadherin...)
in patients treated with this association with the aim to
select chemosensitive patients.
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